Matt WillemsenAlzheimer’s Breakthrough: New Blood Biomarker Discovered
By testing the blood of more than 1,000 cognitively unimpaired elderly people with and without amyloid pathology, the Pitt-led research team found that only those who had a combination of amyloid burden and blood markers of abnormal astrocyte activation, or reactivity, would progress to symptomatic Alzheimer’s in the future, a critical discovery for drug development aimed at halting progression.
https://scitechdaily.com/alzheimers-breakthrough-new-blood-biomarker-discovered/#alzheimers #BloodBiomarker #astrocyte #amyloid
By testing the blood of more than 1,000 cognitively unimpaired elderly people with and without amyloid pathology, the Pitt-led research team found that only those who had a combination of amyloid burden and blood markers of abnormal astrocyte activation, or reactivity, would progress to symptomatic Alzheimer’s in the future, a critical discovery for drug development aimed at halting progression.
https://scitechdaily.com/alzheimers-breakthrough-new-blood-biomarker-discovered/#alzheimers #BloodBiomarker #astrocyte #amyloid
Alzheimer’s Breakthrough: New Blood Biomarker Discovered
What determines whether an individual will develop Alzheimer's disease, and why do many with the disease's characteristic toxic amyloid accumulations in the brain never exhibit associated dementia symptoms? These perplexing questions have long puzzled researchers. Scientists from the University o